Positive Results from GSK Phase 2 Clinical Trial of Seasonal Influenza mRNA Vaccine
- Hidden Perils After COVID-19: A Surge in Dementia and Mental Disorders
- Clozapine Tied to Higher Risk of GI Issues and Pneumonia
- Cassava Sciences Faces $40 Million Fine Over Alleged Fraud in Alzheimer’s Drug Trials
- Can Cytokine Modulation Enhance the Efficacy of CAR-T Cell Therapy?
- What Are HIV-Related Cancers and How Can They Be Prevented?
- Metformin: From Diabetes Treatment to a New Approach for HIV Cure
Positive Results from GSK Phase 2 Clinical Trial of Seasonal Influenza mRNA Vaccine
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Positive Results from GSK Phase 2 Clinical Trial of Seasonal Influenza mRNA Vaccine
In April 2024, GlaxoSmithKline (GSK) announced that its candidate mRNA influenza vaccine outperformed an approved inactivated influenza vaccine in preventing influenza A in a Phase 2 clinical trial. However, it did not achieve the same success against the historically challenging influenza B. GSK’s partner, CureVac, has since committed to optimizing the mRNA vaccine to improve its efficacy against influenza B.
On September 11, 2024, GSK released new data from a Phase 2 trial showing that the optimized mRNA influenza vaccine elicited an immune response comparable to conventional flu vaccines against both influenza A and B in both young and elderly participants.
The trial involved 250 healthy adults aged 18-64 and 250 healthy adults aged 65-85. Results showed that the mRNA vaccine candidate produced an acceptable immune response against both influenza A and B viruses. GSK also noted that interim data demonstrated acceptable safety and reactogenicity for the various mRNA formulations tested.
In July 2024, GSK acquired all rights to CureVac’s candidate mRNA influenza and COVID-19 vaccines for $430 million. GSK plans to continue investing in and collaborating on mRNA technology, focusing on AI-driven mRNA sequence optimization and nanoparticle delivery system design and manufacturing.
GSK highlighted that the latest trial results confirmed the mRNA platform’s ability to generate a strong antibody response with acceptable safety. The company is now preparing to advance the vaccine to Phase 3 clinical trials.
Dr. Tony Wood, GSK’s Chief Scientific Officer, emphasized that the trial marks a significant advancement in their mRNA program. He stated, “These data support our move to late-stage development. Our ultimate goal is to develop a best-in-class vaccine that provides greater protection during flu season.”
GSK faces similar challenges with influenza B as its competitors in the race to bring the first mRNA flu vaccine to market. However, Moderna has been the only company to fully succeed. A year ago, Moderna’s improved candidate mRNA flu vaccine induced higher antibody levels against key influenza B strains than GSK’s approved inactivated flu vaccine, Fluarix, in a Phase 3 trial. Meanwhile, Pfizer and BioNTech’s mRNA flu vaccine showed efficacy against influenza B in their Phase 3 trial, but only in people under 65.
Positive Results from GSK Phase 2 Clinical Trial of Seasonal Influenza mRNA Vaccine
—————
(source:internet, reference only)(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
